Human immunodeficiency virus type 1 (HIV-1) 2 -infected resting CD4 ϩ memory T-cells form a persistent viral reservoir that is a major barrier to curing HIV-1 infection although they do not permit viral replication (1). A small, RNA-binding protein, Tat (transactivator of transcription) (2), plays a central role in the regulation of HIV-1 replication and in potential approaches to treating latently infected cells. During transcription of the viral DNA, RNA polymerase II stalls as a result of binding the negative transcription elongation factor, resulting in the production of prematurely terminated transcripts that may include the tat message (3). Following translation, the Tat protein is transported from the cytoplasm into the nucleus, where it binds a stem-loop structure (transactivation response element (TAR)) formed by the first 59 nucleotides of the HIV-1 RNA (4). Tat stimulates elongation of full-length transcripts by recruiting the positive transcription elongation factor b, a complex of a regulatory cyclin and cyclin-dependent kinase 9, that phosphorylates the C-terminal domain of RNA polymerase II, components of negative transcription elongation factor, and the transcription elongation factor Spt5 (5-7). Recent results suggest that Tat activates positive transcription elongation factor b by displacing Hexim1 (hexamethylene bisacetamide-inducible protein 1) from its cyclin T1 binding site (8) and that the affinity of the Tat-cyclin T1-cyclindependent kinase 9 complex for TAR is regulated through Tat acetylation by histone acetyltransferases (9, 10). The absence of Tat and low levels of cyclin-dependent kinase 9 and cyclin T1 in resting CD4ϩ T-cells are both implicated in HIV-1 latency (1). Tat may also be involved in derepression of heterochromatin, transcription initiation (11), and reverse transcription (12). In addition to its intracellular activities, the literature contains a plethora of reports of extracellular Tat activities, including general cytotoxicity, that may contribute to immune suppression (13,14) and the development of HIV-dementia (15). A molecular understanding of Tat activity requires a determination of its structure and interactions with cellular and viral partners (16, 17). HIV-1 Tat is a 101-residue protein encoded by two exons (3, 18). The first exon defines amino acids 1-72 that encompass an acidic and proline-rich N terminus (amino acids 1-21), a cysteine-rich region (amino acids 22-37), a core (amino acids 38 -47), a basic region (amino acids 48 -57), and a Gln-rich segment (amino acids 58 -72) (19); it activates transcription with the same proficiency as the full-length protein (3, 20 -22). Residues 1-24 form the co-activator and acetyltransferase CREB-binding protein KIX domain binding site (17). Cyclin T1 is thought to interact with the Cys-rich region of Tat (23), and mutation of any one of six of the seven Cys residues results in inactivation (3). The end of the Cys-rich region and the core are involved in mitochondrial apoptosis of bystander noninfected cells through thei...